[go: up one dir, main page]

Büyüktimkin et al., 2014 - Google Patents

Bifunctional peptide inhibitors suppress interleukin-6 proliferation and ameliorates murine collagen-induced arthritis

Büyüktimkin et al., 2014

View HTML
Document ID
12787833895739673090
Author
Büyüktimkin B
Kiptoo P
Siahaan T
Publication year
Publication venue
Journal of clinical & cellular immunology

External Links

Snippet

The objective of this study is to evaluate the efficacy and potential mechanism of action of type-II collagen bifunctional peptide inhibitor (CII-BPI) molecules in suppressing rheumatoid arthritis in the collagen-induced arthritis (CIA) mouse model. CII-BPI molecules (CII-BPI-1 …
Continue reading at pmc.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Similar Documents

Publication Publication Date Title
Pozsgay et al. Antigen-specific immunotherapies in rheumatic diseases
Weinberg OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines
Gokhale et al. Peptides and peptidomimetics as immunomodulators
Kang et al. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets
Schall et al. Peptide-based approaches to treat lupus and other autoimmune diseases
JP6364352B2 (en) Partial MHC construct and method of use thereof
KR20030007899A (en) Methods for Regulationg a Cell-Mediated Immune Response by Blocking Lymphocytic Signals and by Blocking LFA-1 Mediated Adhesion
Mauri et al. Cells of the synovium in rheumatoid arthritis. B cells
JP2015529676A (en) Agents and methods
Lenert et al. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
JP2021050217A (en) Methods for the modulation of lgals3bp to treat systemic lupus erythematosus
del Carmen Domínguez et al. Biodistribution and pharmacokinetic profiles of an altered peptide ligand derived from heat-shock proteins 60 in Lewis rats
Büyüktimkin et al. Bifunctional peptide inhibitors suppress interleukin-6 proliferation and ameliorates murine collagen-induced arthritis
ES2330748T3 (en) ANTIGENIC PEPTIDES OF REUMATOID ARTHRITIS (AR).
US20140004136A1 (en) Phosphorylated derivatives of a u1-70k peptide and their use in the treatment of autoimmune pathologies
Capini et al. Active immunization against murine TNFα peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection
Monneaux et al. Intramolecular T cell spreading in unprimed MRL/lpr mice: Importance of the U1‐70k protein sequence 131–151
Benson et al. Arthritis in space and time–To boldly go!
Abedi-Valugerdi et al. Mercury-induced anti-nucleolar autoantibodies can transgress the membrane of living cells in vivo and in vitro
CN109475549B (en) Pharmaceutical composition and use thereof for treating autoimmune diseases
Kiptoo et al. Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis
Saxena et al. Rheumatoid arthritis: disease pathophysiology
ES2338773T3 (en) MODIFIED PEPTIDES AND ITS USE FOR THE TREATMENT OF AUTOIMMUNITY DISEASES.
Zhu et al. A novel BLyS peptibody down-regulates B cell and T helper cell subsets in vivo and ameliorates collagen-induced arthritis
US10759838B2 (en) Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use